Pharmaceutical Experts Advocate for Flexible Hybrid Models to Replace One-Size-Fits-All DTP Programs

A recent analysis highlights the limitations of traditional direct-to-patient (DTP) programs, which often rely on rigid, one-size-fits-all models. Allison Bridges, Senior Vice President of Client Success at PHIL Inc., and Cindy Eckert, Founder and CEO of Sprout Pharmaceuticals, argue that these static approaches fail to meet evolving patient expectations for convenience, choice, and price transparency. They propose that pharmaceutical manufacturers should adopt more flexible and hybrid access models to enhance both patient experience and commercial outcomes.

Bridges and Eckert emphasize that patients increasingly demand tailored solutions in healthcare delivery. They suggest that outdated DTP frameworks restrict innovation by not accommodating diverse patient needs or preferences. According to their insights, transitioning toward adaptable systems—such as PHIL’s DTP 2.0 platform—could address these challenges by offering greater flexibility in how patients access medications. This approach aims to align better with modern consumer expectations while improving operational efficiency for manufacturers.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

For any suggestion and feedback, please contact us.

Date: February 27, 2026

Author

GOAI